http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101661199-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2500-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2506-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0644 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0018 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-078 |
| filingDate | 2015-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101661199-B1 |
| titleOfInvention | Method for producing megakaryocytes and thrombocytes derived from human myelogenous leukemia cells |
| abstract | The present invention relates to a method for inducing differentiation of human myeloid leukemia cell line into megakaryocytes and platelets. More particularly, the present invention relates to a method for inducing the differentiation of human myeloid leukemia cell line into megakaryocytes and thrombocytes by treating a composition comprising phytosphingosine as an active ingredient, And the phytosphingosine can exhibit high efficiency even at a low concentration as compared with the conventional megakaryocytic differentiation inducing compound. In addition, co-culturing with OP9 cells is not required, and it is possible to induce megakaryocyte differentiation only by using alone, and these megakaryocytes and platelets generated therefrom can be used for treatment of thrombocytopenia and the like. |
| priorityDate | 2015-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 41.